Who are Placebo matching with Abatacept's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orencia, Double-blind Abatacept, Abatacept SC, Intravenous (IV) abatacept, abatacept infusion, IV Abatacept.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matching-with-abatacept.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo matching with Abatacept — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo matching with Abatacept (Placebo matching with Abatacept) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CTLA-4 fusion protein; T-cell costimulation inhibitor. Area: Immunology.

marketed CTLA-4 fusion protein; T-cell costimulation inhibitor CD80, CD86 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matching with Abatacept (Placebo matching with Abatacept) — Bristol-Myers Squibb. Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo matching with Abatacept TARGET	Placebo matching with Abatacept	Bristol-Myers Squibb	marketed	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
Orencia	abatacept	Bristol-Myers Squibb	marketed	Selective T cell costimulation modulator	CD80, CD86, CD28	2005-01-01
Double-blind Abatacept	Double-blind Abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein (T-cell co-stimulation inhibitor)	CD80, CD86
Abatacept SC	Abatacept SC	University Medical Center Groningen	phase 3	Costimulation modulator; T cell inhibitor	CD80, CD86
Intravenous (IV) abatacept	Intravenous (IV) abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
abatacept infusion	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86
IV Abatacept	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CTLA-4 fusion protein; T-cell costimulation inhibitor class)

Bristol-Myers Squibb · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matching with Abatacept — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matching-with-abatacept. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab